Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_assertion type Assertion NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_head.
- NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_assertion description "[Targeted therapy of chronic myeloid leukemia (CML) is currently based on small-molecule inhibitors that directly bind the tyrosine kinase domain of BCR-ABL1.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_provenance.
- NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_assertion evidence source_evidence_literature NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_provenance.
- NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_assertion SIO_000772 25721898 NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_provenance.
- NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_assertion wasDerivedFrom befree-2016 NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_provenance.
- NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_assertion wasGeneratedBy ECO_0000203 NP1266657.RA4V8aQs4I_jkRF8v1Z1HJqfk4PcBH21zUxQtSDukgN28130_provenance.